Form 4: Avidity Biosciences Chief Program Officer Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, Inc., sold 911 shares of common stock for $30.24 per share on June 17, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.
Summary
- Kathleen P. Gallagher, the Chief Program Officer of Avidity Biosciences, Inc. (Ticker: RNA), reported a sale of common stock.
- The transaction occurred on June 17, 2025.
- A total of 911 shares of common stock were disposed of.
- The shares were sold at a price of $30.24 per share, totaling $27,558.64.
- Following this transaction, Ms. Gallagher beneficially owns 50,392 shares of common stock.
- The sale was executed pursuant to a Rule 10b5-1 trading plan, which was previously adopted by Ms. Gallagher on June 12, 2024.
Sentiment
Score: 5
Explanation: The document reports a routine, pre-planned sale of a relatively small number of shares by an officer, which is neutral in sentiment as it does not indicate new information or a significant change in confidence.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating that the transaction was scheduled in advance and not based on new, non-public information, which enhances transparency.
Negatives
- An insider, the Chief Program Officer, sold shares, which can sometimes be interpreted by the market as a lack of confidence, although this is mitigated by the pre-arranged 10b5-1 plan.
Risks
- Potential for market misinterpretation of insider selling, despite the transparency provided by the Rule 10b5-1 plan.
Future Outlook
N/A
Industry Context
N/A
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in insider ownership, but its execution under a 10b5-1 plan suggests it is a routine financial management decision rather than a signal of changing company prospects.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 06/17/2025 | Date of the reported transaction (sale of common stock). |
| 06/18/2025 | Date the Form 4 filing was signed. |
Keywords
Avidity Biosciences, RNA, Form 4, insider trading, stock sale, Kathleen P. Gallagher, 10b5-1 plan, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.